{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:27:25Z","timestamp":1789882045769,"version":"4.0.1"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>People with inherited bleeding disorders have been disproportionally affected by <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>. We assessed the fixed\u2010dose combination of the NS5A inhibitor ledipasvir (<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>) with the NS5B polymerase inhibitor sofosbuvir (<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>) with ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) in patients with genotype 1 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> and inherited bleeding disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To be eligible, patients had to be over 18\u00a0years of age and have an inherited bleeding disorder. <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment\u2010na\u00efve and \u2010experienced patients could enrol. All patients received <jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> 90\u00a0mg per <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content> 400\u00a0mg once daily and weight\u2010based <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> in a divided dose for 12\u00a0weeks. The primary efficacy endpoint was sustained virologic response (SVR), defined as <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> below the limit of detection (15\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup>) 12\u00a0weeks after the end of treatment (SVR12).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 14 patients enrolled, 8 (57%) had haemophilia A, 3 (21%) had haemophilia B and 2 (14%) had von Willebrand disease, and 1 (7%) had factor XIII deficiency. All 14 patients (100%, 95% CI: 77\u2013100%) achieved SVR12. Treatment was well tolerated: all patients completed therapy, with mostly mild adverse events. No specific safety concerns associated with the patient's underlying bleeding disorders were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results appear to suggest that people with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> and inherited bleeding disorders can be safely and effectively treated with 12\u00a0weeks of <jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.12791","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T10:57:23Z","timestamp":1440759443000},"page":"214-217","source":"Crossref","is-referenced-by-count":35,"title":["Once daily ledipasvir\/sofosbuvir fixed\u2010dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection"],"prefix":"10.1111","volume":"22","author":[{"given":"C. A. M.","family":"Stedman","sequence":"first","affiliation":[{"name":"Gastroenterology Department Christchurch Hospital and University of Otago Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"Hyland","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ding","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Pang","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"McHutchison","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Gane","sequence":"additional","affiliation":[{"name":"New Zealand Liver Transplant Unit Auckland City Hospital Auckland New\u00a0Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02854.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn119"},{"key":"e_1_2_8_5_1","volume-title":"Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12791","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:14:28Z","timestamp":1695561268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/hae.12791"],"URL":"https:\/\/doi.org\/10.1111\/hae.12791","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}